Alpine Immune Sciences Inc
ALPN
$64.57
Closing
▲0.03%
1D
▲238.77%
YTD
Market cap
$4.23B
52 week high
$64.70
52 week low
$6.71
Volume
327,543
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$4.23B
Analysts' Rating
BUY
Price Target (Mean)
24
Total Analysts
7
P/E
Operating Margin
-144.88%
Beta
0.96
Revenue Growth (Annual)
28.24%
52 week high
$64.70
52 week low
$6.71
Div. Yield
%
EPS Annual Growth
-11.11
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
